EA202092964A1 - Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака - Google Patents

Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака

Info

Publication number
EA202092964A1
EA202092964A1 EA202092964A EA202092964A EA202092964A1 EA 202092964 A1 EA202092964 A1 EA 202092964A1 EA 202092964 A EA202092964 A EA 202092964A EA 202092964 A EA202092964 A EA 202092964A EA 202092964 A1 EA202092964 A1 EA 202092964A1
Authority
EA
Eurasian Patent Office
Prior art keywords
platinum
cancer
antineoplastic agents
basis
treatment
Prior art date
Application number
EA202092964A
Other languages
English (en)
Russian (ru)
Inventor
Жоан Сеоане Суарез
Джудит Анидо Фолгуэйра
Робин Мэттью Халлетт
Патрисиа Энн Гиблин
Жанн Маграм
Наимиш Пандйа
Роберт Вассерман
Ангус Синклер
Original Assignee
Медиммун Лимитед
Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн
Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед, Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн, Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс filed Critical Медиммун Лимитед
Publication of EA202092964A1 publication Critical patent/EA202092964A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202092964A 2018-06-18 2019-06-17 Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака EA202092964A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382432 2018-06-18
PCT/IB2019/000812 WO2019243900A2 (en) 2018-06-18 2019-06-17 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Publications (1)

Publication Number Publication Date
EA202092964A1 true EA202092964A1 (ru) 2021-03-30

Family

ID=62837845

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092964A EA202092964A1 (ru) 2018-06-18 2019-06-17 Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака

Country Status (12)

Country Link
US (1) US20210187106A1 (enExample)
EP (1) EP3806899A2 (enExample)
JP (2) JP7379390B2 (enExample)
KR (1) KR20210022065A (enExample)
CN (1) CN112955178B (enExample)
AU (2) AU2019291307B2 (enExample)
CA (1) CA3103369A1 (enExample)
EA (1) EA202092964A1 (enExample)
IL (1) IL279444A (enExample)
MA (1) MA52300A (enExample)
SG (1) SG11202012576QA (enExample)
WO (1) WO2019243900A2 (enExample)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
AU2015314980A1 (en) * 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
CA2983126A1 (en) 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3794031A2 (en) * 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof

Also Published As

Publication number Publication date
CN112955178A (zh) 2021-06-11
JP7603772B2 (ja) 2024-12-20
JP2024023212A (ja) 2024-02-21
JP7379390B2 (ja) 2023-11-14
MA52300A (fr) 2021-04-21
EP3806899A2 (en) 2021-04-21
WO2019243900A3 (en) 2020-03-05
AU2019291307B2 (en) 2024-04-04
JP2021533084A (ja) 2021-12-02
AU2024204564A1 (en) 2024-07-18
CN112955178B (zh) 2025-03-11
WO2019243900A2 (en) 2019-12-26
US20210187106A1 (en) 2021-06-24
KR20210022065A (ko) 2021-03-02
CA3103369A1 (en) 2019-12-26
AU2019291307A1 (en) 2021-02-04
IL279444A (en) 2021-01-31
SG11202012576QA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CY1125356T1 (el) Παραγωγα ν-πυριδινυλιου ως αναστολεις της οδου σηματοδοτησης wnt
CY1125116T1 (el) Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2022005360A (es) Inhibidores de ras.
MX2022005359A (es) Inhibidores de ras.
MX2022005357A (es) Inhibidores de ras.
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
EA202191852A1 (ru) Необратимые ингибиторы взаимодействия менин-mll
CY1122243T1 (el) Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
MX2019013858A (es) Inhibidores de kras g12c y metodos para su uso.
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
MX391470B (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
DK3890740T3 (da) CD70 og venetoclax, en BCL-2 inhibitor, kombinationsterapi til behandling af akut myeloid leukæmi
MX2021006731A (es) Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
EP4585273A3 (en) Mechanism of resistance to bet bromodomain inhibitors
LT3962601T (lt) 5-ht2a agonistai, skirti panaudoti depresijos gydymui
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
UY38352A (es) Inhibidores de integrina alfavbeta6
ZA201904533B (en) Antibodies against lif and uses thereof
IL289242A (en) Combination therapy methods, compositions and kits